Kyntra Bio, Inc. (KYNB) — Cash Flow-to-Debt Ratio
Kyntra Bio, Inc. (KYNB) has a Cash Flow-to-Debt Ratio of -0.16x as of December 2025, meaning its operating cash flow of $-18.33 Million could theoretically repay 0% of its total liabilities ($115.12 Million) in one year. Explore KYNB long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kyntra Bio, Inc. Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Kyntra Bio, Inc. across 14 annual periods. Also explore balance sheet size of Kyntra Bio, Inc. for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Kyntra Bio, Inc. (2012–2025)
Year-by-year debt coverage analysis for Kyntra Bio, Inc.. For market capitalisation and broader financial context, see market cap of Kyntra Bio, Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.04x | $-4.77 Million | $115.12 Million | ▲ +88.0% |
| 2024 | -0.35x | $-138.00 Million | $398.16 Million | ▲ +35.6% |
| 2023 | -0.54x | $-315.02 Million | $585.73 Million | ▼ -125.4% |
| 2022 | -0.24x | $-145.93 Million | $611.57 Million | ▼ -58.1% |
| 2021 | -0.15x | $-82.23 Million | $544.71 Million | ▼ -171.3% |
| 2020 | 0.21x | $81.60 Million | $385.39 Million | ▲ +186.6% |
| 2019 | -0.24x | $-78.70 Million | $321.99 Million | ▼ -13.0% |
| 2018 | -0.22x | $-76.14 Million | $352.13 Million | ▼ -2.8% |
| 2017 | -0.21x | $-66.51 Million | $316.20 Million | ▼ -971.4% |
| 2016 | 0.02x | $7.11 Million | $294.44 Million | ▲ +135.6% |
| 2015 | -0.07x | $-18.57 Million | $273.75 Million | ▼ -173.5% |
| 2014 | 0.09x | $22.41 Million | $242.85 Million | ▼ -32.6% |
| 2013 | 0.14x | $25.92 Million | $189.35 Million | ▲ +450.2% |
| 2012 | -0.04x | $-5.61 Million | $143.40 Million | — |